Better Health for All

Eli Lilly's core business of developing pharmaceutical products for diseases like diabetes, cancer, and immunology provides substantial health benefits, with over 55 million people using its medicines in 2023.

The company has no reported revenue from products with negative health outcomes. In 2023, Eli Lilly provided $4.3 billion in free medicines, representing 12.6% of its revenue, supporting extensive health equity programs. It has implemented a $35 monthly cap on out-of-pocket costs for all its insulins in the US, regardless of insurance, and reduced list prices for most prescribed insulins by 70% in 2023, helping over 1 million American adults. Its 30x30 initiative reached 18 million people in resource-limited settings in 2023, with a goal of 30 million annually by 2030, and it supports the deployment of 140,000 Community Healthcare Workers in Tanzania by 2028. For clinical trials, Lilly achieved approximately 39% minority participation across its US trials, actively working to increase diversity and address historical mistrust. The company does not pursue or enforce patents in least developed countries and licenses baricitinib manufacturing know-how to EVA Pharma for 49 low- and middle-income countries in Africa. Lilly maintains excellent risk transparency, including safety summaries for its products, and received no warning letters from the FDA's Office of Prescription Drug Promotion in 2023. Furthermore, it repurposed 97.1% of plastic waste and recycled or reused 97.5% of water at its facilities in 2023, while reducing greenhouse gas emissions by 26% since 2020.

Fair Money & Economic Opportunity

Eli Lilly and Company is a pharmaceutical company, and its core business does not involve lending, insuring, moving, or storing money in the manner typically assessed by the provided KPIs. While the company engages in activities such as reducing insulin prices by 70%

and capping out-of-pocket costs at $35 per month, providing $4.2 billion in free medicines in 2024, and investing in community health initiatives and job creation programs for underserved populations, these actions, while aligning with the spirit of affordable pricing and economic opportunity, do not directly map to the specific quantitative thresholds of the KPIs. The KPIs are designed for financial institutions, requiring metrics like APRs, loan book shares, credit outcomes, or banking access points, for which no direct evidence is available for Eli Lilly's operations. Therefore, all KPIs are omitted.

Fair Pay & Worker Respect

Eli Lilly and Company settled three age discrimination lawsuits in 2023

, including a $2.4 million settlement with the EEOC. The company's Total Recordable Injury Rate (TRIR) for US and Puerto Rico was 1.18 in 2024 , with zero fatalities reported from 2020 to 2024. The voluntary employee attrition rate was 7% in 2024.

Fair Trade & Ethical Sourcing

Lilly's global quality auditing and compliance team conducts annual risk-based audits for external third-party operations.

For Lilly ANZ, all agreements require suppliers to comply with applicable laws and Lilly's Supplier Code of Business Conduct.

Honest & Fair Business

Eli Lilly was ordered to pay $183 million in 2023 for defrauding Medicaid by underreporting drug prices.

The company's anti-corruption program includes a risk-based approach implemented in all geographies, with 100% of required employees completing scenario-based anti-corruption training in 2024, and comprehensive anti-bribery commitments for suppliers. Eli Lilly maintains a 24/7 global ethics and compliance hotline, staffed by an independent firm, offering anonymous reporting and translation services. In 2024, 348 high-risk allegations were investigated, with 80% confirmed violations leading to disciplinary action. The company's 2023 annual report did not mention any financial restatements. The entire consolidated financial statements are audited by an independent external accounting firm.

Kind to Animals

Eli Lilly has converted 80% of its endotoxin testing from horseshoe crab blood to recombinant Factor C (rFC) since 2016

, using this method for at least eight global approvals and in all its injectable manufacturing facilities and new injectable medicines . The company also utilizes other non-animal methods such as in vitro, in silico, microphysiological systems, organ-on-chip technology, and organoids . All Eli Lilly animal sites are accredited by AAALAC International . The company maintains a global oversight program for all animal research and supply companies, conducting regular welfare evaluations and audits of Contract Research Organizations (CROs) and suppliers, including all animal suppliers and feed vendors . Eli Lilly has a global Animal Care and Use Standard based on the 3Rs principles (Replacement, Reduction, Refinement), overseen by ethical committees . However, the company faced criticism for conducting the forced swim test on 3,400 animals between 1993 and 2019 , and had not banned this practice by 2019 . In 2021, reports indicated the use of over 2,200 animals, including dogs and primates, with some enduring unalleviated pain . Eli Lilly participates in numerous national and international organizations and consortia focused on animal care, 3Rs, and alternative methods, including the IQ Consortium's 3Rs working group , and supports the broader use of rFC in the pharmaceutical industry .

No War, No Weapons

Eli Lilly and Company is a pharmaceutical firm that explicitly states it does not engage in the production of weapons or military equipment.

The company has entered into contracts with the U.S. Department of Defense, including a $625 million contract in 2025 and a $1.08 billion contract in 2022, but these were for COVID-19 therapeutics and public health initiatives, not military operations or weapons manufacturing. In 2024, Eli Lilly provided $30.9 million for disaster relief and humanitarian assistance, which represents approximately 0.09% of its 2023 revenue. The company has been a member of the UN Global Compact since 2009, supporting its principles, though shareholder proposals in 2023 highlighted requests for more comprehensive human rights policies and impact assessments. As a pharmaceutical company with no involvement in weapons, specific ethical red lines or compliance rates related to weapons are not applicable to its business model.

Planet-Friendly Business

Eli Lilly's total Scope 1, 2, and 3 greenhouse gas emissions for 2024 were 6,624,000 tCO2e.

The company sourced 58.3% of its electricity demand from renewable sources in 2024. Its water withdrawal efficiency was 168.8 m³ per $1 million revenue in 2024, with 7.5% of water use originating from water-stressed areas, where all manufacturing sites have water management plans. The company achieved a waste diversion rate of 98.9% from routine operations in 2024, with 1.1% of waste sent to landfill. Eli Lilly has not purchased any carbon offsets to date. The company reported zero fines, penalties, or enforcement actions for water-related environmental violations in 2023, 2024, and 2025. Eli Lilly has a target to achieve carbon neutrality for its Scope 1 and 2 emissions by 2030. The company discloses information according to the Task Force on Climate-related Financial Disclosures (TCFD), integrating climate-risk into its Enterprise Risk Management, and has a climate transition plan aligned with a 1.5°C world, assessing water-related scenarios.

Respect for Cultures & Communities

Eli Lilly engaged in 12 formal partnerships or grants with local community groups, including a partnership with The Center for Drug Development and Clinical Trials at Roswell Park Cancer Institute

, sponsoring the African American Health Coalition's "Wellness on Wheels" event in 2025 , and providing grants to four Indiana nonprofits for DACA recipients in 2023 . The company spent approximately $1.5 billion with about 1,600 small and/or diverse suppliers in 2023 . No cultural site disruptions were reported, and the Eli Lilly Foundation granted $1 million in 2021 to support the expansion of the Indianapolis Cultural Trail, which preserves local heritage .

Safe & Smart Tech

While Eli Lilly provides users with state-specific rights to know, delete, correct, opt out of profiling, limit use of sensitive personal information, and opt out of sale/sharing/targeted advertising, the company states it may sell sensitive personal information and does not honor Do Not Track signals.

In October 2024, Eli Lilly appointed its first Chief AI Officer to oversee AI initiatives and emphasize responsible AI development. The company complies with the EU-U.S. Data Privacy Framework, its UK Extension, the Swiss-U.S. DPF, and the Department of Justice’s Data Security Program (28 C.F.R., Part 202). Historically, in 2002, the company settled FTC charges concerning a 2001 breach that exposed email addresses, agreeing to implement consumer privacy protection measures.

Zero Waste & Sustainable Products

Eli Lilly achieved a 97.84% waste diversion rate from landfill for its total waste in 2024.

The company has set 2030 targets, including zero waste to landfill from routine operations (defined as less than 0.5% sent to landfill) and repurposing 100% of plastic waste with at least 90% recycled or reused. In 2024, 20 out of 32 facilities (62.5%) achieved zero-landfill status. Lilly integrates sustainability-focused design principles early in product development, supported by a Design for Sustainability Guidebook and lifecycle analyses. The company has implemented numerous waste reduction initiatives, such as eliminating polystyrene foam and single-use plastic cups at various facilities, transitioning to aluminum cans, composting food waste, optimizing packaging, and forming a green logistics team. Lilly also provides comprehensive information to patients and caregivers on proper disposal of medicines and sharps through product user manuals, medicine resources, and a Safe Sharps Disposal Plan. Pilot take-back programs for injection pens are active in Germany, Denmark, and France , and Lilly participates in mandated household medicine and sharps take-back programs in the US.